Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 85Stomach Neoplasms 16Esophageal Neoplasms 14Neoplasms 10Cholangiocarcinoma 10Carcinoma, Non-Small-Cell Lung 10Breast Neoplasms 9Neoplasm Metastasis 8Adenocarcinoma Of Esophagus 8Esophageal Squamous Cell Carcinoma 7Endometrial Neoplasms 7Colorectal Neoplasms 7Pancreatic Adenocarcinoma 6Ovarian Neoplasms 6Lung Neoplasms 6Gallbladder Neoplasms 6Carcinoma, Ovarian Epithelial 6Adenocarcinoma 5Squamous Cell Carcinoma of Head and Neck 4Prostatic Neoplasms 4Melanoma 4Biliary Tract Neoplasms 4Urinary Bladder Neoplasms 3Sarcoma 3Liver Neoplasms 3Gastric Adenocarcinoma 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Anus Neoplasms 3Advanced Pancreatic Cancer 3

Interventions

folfirinox 1Taxes 1Oxaliplatin 1Neoadjuvant Therapy 1Leucovorin 1Irinotecan 1Gemcitabine 1FAPI-46 1Endosonography 1Blood Specimen Collection 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Ductal Adenocarcinoma (PDAC) × Taxes × Gastrointestinal × Clear all
NCT06182072 2025-10-01

ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

ProDa BioTech, LLC

Phase 1 Recruiting
46 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma (PDAC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡